Prevalence and Profile of Aspirin Resistance in Hemodialysis Patients

This study has been completed.
Sponsor:
Collaborator:
Staten Island University Hospital
Information provided by (Responsible Party):
Suzanne El-Sayegh, North Shore Long Island Jewish Health System
ClinicalTrials.gov Identifier:
NCT00792272
First received: November 14, 2008
Last updated: July 19, 2013
Last verified: July 2013
  Purpose

Dialysis patient could be more aspirin resistant than the general population based on data from chronic kidney disease patients


Condition
Aspirin Resistance

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Prevalence of Aspirin Resistance in Hemodialysis Patients

Resource links provided by NLM:


Further study details as provided by North Shore Long Island Jewish Health System:

Primary Outcome Measures:
  • Aspirin Resistance in Hemodialysis patients [ Time Frame: 2 months ] [ Designated as safety issue: No ]

Enrollment: 100
Study Start Date: June 2008
Study Completion Date: November 2008
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Detailed Description:

We will try to describe the profile of aspirin resistant patient in hemodialysis patients

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

all hemodialysis patients on aspirin

Criteria

Inclusion Criteria:

  • all hemodialysis patients on aspirin

Exclusion Criteria:

  • low platelets <100.000
  • coagulopathy, bleeding disorders
  • patient on plavix
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00792272

Sponsors and Collaborators
North Shore Long Island Jewish Health System
Staten Island University Hospital
Investigators
Principal Investigator: Suzanne El-Sayegh, MD SIUH
  More Information

No publications provided

Responsible Party: Suzanne El-Sayegh, Assoc. Chair of Medicine, North Shore Long Island Jewish Health System
ClinicalTrials.gov Identifier: NCT00792272     History of Changes
Other Study ID Numbers: 08-013
Study First Received: November 14, 2008
Last Updated: July 19, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by North Shore Long Island Jewish Health System:
aspirin resistance
aspirin resistance in hemodialysis patients

Additional relevant MeSH terms:
Aspirin
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Inflammatory Agents
Therapeutic Uses
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Cardiovascular Agents
Hematologic Agents
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Antipyretics
Central Nervous System Agents

ClinicalTrials.gov processed this record on July 28, 2014